Abstract
Background There is potentially considerable variation in the nature and duration of the care provided to hospitalised patients during an ongoing infectious disease epidemic or pandemic. Improvements in care and clinician confidence may shorten the time spent as an inpatient, or the need for admission to an intensive care unit (ICU) or high density unit (HDU), while novel treatment modalities may reduce the time course of illness. On the other hand, limited resources at times of high demand may lead to rationing of resources, with less beneficial consequences. Despite little evidence on how the values of such variables change over the course of a crisis (such as the current COVID-19 pandemic), they may nevertheless be used as proxies for disease severity, outcome measures for clinical trials, and to inform planning and logistics. We hypothesise that variation of this kind has been present over the first year of the pandemic.
Methods and Findings We investigate such time trends in an extremely large international cohort of 142,540 patients with symptom onset of, or hospital admission for, COVID-19 during 2020. The variables investigated are time from symptom onset to hospital admission, probability of ICU/HDU admission, time from hospital admission to ICU/HDU admission, case fatality ratio (CFR) and total length of hospital stay. Time from hospital symptom onset to hospital admission showed a rapid decline during the first months of the pandemic followed by peaks during August/September and December. ICU/HDU admission was more frequent from June to August, while there were only modest time trends in time from hospital admission to ICU/HDU. The CFR was lowest from June to August, a trend mostly driven by patients with no ICU/HDU admission. Raw numbers for overall hospital stay showed little overall variation over the time period, but further examination reveals a clear decline in time to discharge for ICU/HDU survivors. The main limitations are that these are predominantly severe COVID-19 cases, and that there are temporal, spatial and demographic biases present in an observational study of this kind.
Conclusions Our results establish that variables of these kinds have limitations when used as outcome measures in a rapidly-evolving situation.
Competing Interest Statement
Allavena, C. declares personal fees from ViiVHealthcare, MSD, Janssen and Gilead, all outside the submitted work.
Andréjak, C. declares personal fees for lecture from Astra Zeneca, outside the submitted work.
Cheng, M. declares grants from McGill Interdisciplinary Initiative in Infection and Immunity, grants from Canadian Institutes of Health Research, during the conduct of the study; personal fees from GEn1E Lifesciences (as a member of the scientific advisory board), personal fees from nplex biosciences (as a member of the scientific advisory board), outside the submitted work. He is the co-founder of Kanvas Biosciences and owns equity in the company. In addition, M. Cheng reports a patent Methods for detecting tissue damage, graft versus host disease, and infections using cell-free DNA profiling pending, and a patent Methods for assessing the severity and progression of SARS-CoV-2 infections using cell-free DNA pending.
Cholley, B. declares personal fees (for lectures and participation to advisory boards) from Edwards, Amomed, Nordic Pharma, and Orion Pharma.
Cruz-Bermúdez, J.L. declares personal fees from Elsevier for advice, outside the submitted work.
Cummings, M. and O’Donnell, M. participated as investigators for clinical trials evaluating the efficacy and safety of remdesivir (sponsored by Gilead Sciences) and convalescent plasma (sponsored by Amazon) in hospitalized patients with COVID-19. Support for this work is paid to Columbia University.
Dalton, H. declares personal fees for medical director of Innovative ECMO Conceots and honorarium from Abiomed/BREETHE Oxi-1 and Instrumentation Labs.
Dyrhol-Riise, AM. declares grants from Gilead outside this work.
Deplanque, D. declares personal fees from Biocodex, Bristol-Myers Squibb and Pfizer (advisory boards).
Dudman, S. reports grants from Research Council of Norway grant no 312780.
Durante-Mangoni, E. declares funding via his Institution from MSD, Pfizer, and personal fees or participation in advisory boards or participation to the speaker’s bureau of Roche, Pfizer, MSD, Angelini, Correvio, Nordic Pharma, Bio-Merieux, Abbvie, Sanofi-Aventis, Medtronic, Tyrx and DiaSorin.
Grasselli, G. declares personal fees from Getinge, Biotest, Draeger Medical, Fisher & Paykel, MSD and unrestricted research grant from MSD and Fisher & Paykel, all outside the submitted work.
Guerguerian, AM. participated as site investigator for the Hospital For Sick Children, Toronto, Canada as a site through SPRINT-SARI Study via the Canadian Critical Care Trials Group sponsored in part by the Canadian Institutes of Health Research.
Ho, A. declares grant funding from Medical Research Council UK, Scottish Funding Council - Grand Challenges Research Fund, and the Wellcome Trust, outside this submitted work.
Holter, J. C. reports grants from Research Council of Norway grant no 312780, and from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner, during the conduct of the study.
Kimmoun, A. declares personal fees (payment for lectures) from Baxter, Aguettant, Aspen.
Kumar, D. declares grants and personal fees from Roche, GSK and Merck; and personal fees from Pfizer and Sanofi.
Kutsogiannis, D.J. declares personal fees for a lecture from Tabuk Pharmaceuticals and the Saudi Critical Care Society.
Kutsyna, G. declares the study consulting fee for clinical trial ClinicalTrials.gov Identifier: NCT04762628.
Laffey, J. reports that he has received fees for consultancy from GlaxoSmithKline and from Baxter Therapeutics for work outside the scope of this work.
Lairez, O. declares grant funding from Pfizer; conference fees from Amicus, GE Healthcare, Novartis, Sanofi-Genzyme, and Takeda-Shire; and consultancy fees from Alnylam, Amicus, Pfizer, Takeda-Shire.
Lee, J. reports grants from European Commission PREPARE grant agreement No 602525, European Commission RECOVER Grant Agreement No 101003589 and European Commission ECRAID-Plan Grant Agreement 825715 supporting the conduct, coordination and management of the work.
Lee, T.C. declares research salary support from les Fonds de recherche du Québec - Santé.
Lefèvre, B. declares travel/accommodation/meeting expenses from Mylan and Gilead, all outside the submitted work.
Lemaignen, A. declares personal fees (payment for lectures) from MSD and Gilead; and travel/accommodation/meeting expenses from Pfizer.
Lescure, F.X. declares personal fees (payment for lectures) from Gilead, MSD; and travel/accommodation/meeting expenses from Astellas, Eumedica, MSD.
Liu, K. reports personal fees from MERA and receives a salary from TXP Medical completely outside the submitted work.
Martin-Loeches I. declares consulting fees for Gilead outside of the submitted work.
Martín-Quiros, A. declares consulting fees for Gilead.
Mentré F, declares consulting fees from IPSEN, Servier and Da Volterra, and reports research grants to her group from Sanofi, Roche, Servier and Da Voleterra, all outside the submitted work.
Murthy, S declares receiving salary support from the Health Research Foundation and Innovative Medicines Canada Chair in Pandemic Preparedness Research.
Nichol, A. declares a grant from the Health Research Board of Ireland to support data collection in Ireland (CTN-2014-012).
Openshaw, P. has served on scientific advisory boards for Janssen/J&J, Oxford Immunotech Ltd, GSK, Nestle and Pfizer (fees to Imperial College). He is Imperial College lead investigator on EMINENT, a consortium funded by the MRC and GSK. He is a member of the RSV Consortium in Europe (RESCEU) and Inno4Vac, Innovative Medicines Initiatives (IMI) from the European Union.
Peltan, I.D. declares grant support from the National Institutes of Health and, outside the submitted work, grant support from Centers for Disease Control and Prevention, and Jannsen and payments to his institution for trials by Regeneron and Asahi Kasei Pharma on which he served as an investigator.
Pesenti, A. declares personal fees from Maquet, Novalung/Xenios, Baxter, and Boehringer Ingelheim.
Poissy, J. declares personal fees from Gilead for lectures, outside the submitting work.
Povoa, P. declares personal fees (for lectures and advisory boards) from MSD, Technophage, Sanofi, and Gilead.
Póvoas, D. declares consulting fees (for lectures and/or participation in advisory boards) from Roche and Viiv Healthcare; and travel/accommodation/meeting expenses from Abbvie, Gilead Sciences, Janssen Cilag, Merck Sharp & Dohme and ViiV Healthcare.
Rewa, O. declares consulting fees from Baxter Inc.
Rossanese, A. declares consulting fees (for lectures and/or participation to advisory boards) from Emergent BioSolutions and Sanofi Pasteur, but all outside of the frame of the submitted work.
Săndulescu, O. has been an investigator in COVID-19 clinical trials by Algernon Pharmaceuticals, Atea Pharmaceuticals, Regeneron Pharmaceuticals, Diffusion Pharmaceuticals, and Celltrion, Inc., outside the scope of the submitted work.
Semple, M.G. reports grants from DHSC National Institute of Health Research UK, from the Medical Research Council UK, and from the Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool, supporting the conduct of the study; other interest in Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work.
Serpa Neto, A. declares personal lecture fees from Drager outside the submitted work.
Shrapnel, S. participated as an investigator for an observational study analysing ICU patients with COVID-19 (for the Critical Care Consortium including ECMOCARD) funded by The Prince Charles Hospital Foundation during the conduct of this study. S. Shrapnel reports in kind support from the Australian Research Council Centre of Excellence for Engineered Quantum Systems (CE170100009).
Streinu-Cercel, Adrian has been an investigator in COVID-19 clinical trials by Algernon Pharmaceuticals, Atea Pharmaceuticals, Regeneron Pharmaceuticals, Diffusion Pharmaceuticals, and Celltrion, Inc., outside the scope of the submitted work.
Streinu-Cercel, Anca has been an investigator in COVID-19 clinical trials by Algernon Pharmaceuticals, Atea Pharmaceuticals, Regeneron Pharmaceuticals, Diffusion Pharmaceuticals, and Celltrion, Inc., outside the scope of the submitted work.
Summers, C. reports that she has received fees for consultancy for Abbvie relating to COVID-19 therapeutics. She was also the UK Chief Investigator of a GlaxoSmithKline plc sponsored study of a therapy for COVID, and is a member of the UK COVID Therapeutic Advisory Panel (UK-CTAP). Outside the scope of this work, Dr Summers’ institution receives research grants from the Wellcome Trust, UKRI/MRC, National Institute for Health Research (NIHR), GlaxoSmithKline and AstraZeneca to support research in her laboratory.
Tedder, R. reports grants from MRC/UKRI during the conduct of the study. In addition, R. Tedder has a patent United Kingdom Patent Application No. 2014047.1 “SARS-CoV-2 antibody detection assay” issued.
Timsit, J.F. declares personal fees from Merck, Pfizer, Gilead, Beckton dickinson, Medimune, Bayer pharma, and reports research grants to his research unit from Pfizerpers, Merck, Thermofisher.
Troost, J. declares personal fees from General Electric and Procter and Gamble.
Turtle, L. reports fees from Eisai for delivering a lecture related to COVID-19 and cancer, paid to the University of Liverpool.
Ullrich, R. reports grant funding to his institution from Apeptico, APEIRON, Biotest, Bayer, CCORE and Philips, as well as personal fees from Biotest. He holds European patent EP15189777.4 “Blood purification device” and equity in CCORE Technology GesmbH, a medical device research and development company.
Visseaux, B. declares personal fees from BioMérieux, Qiagen and Gilead and research grants from Qiagen, all outside the submitted work.
Funding Statement
This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135]; CIHR Coronavirus Rapid Research Funding Opportunity OV2170359; Grants from Rapid European COVID-19 Emergency Response research (RECOVER) [H2020 project 101003589] and European Clinical Research Alliance on Infectious Diseases (ECRAID) [965313]; The Imperial NIHR Biomedical Research Centre; The Cambridge NIHR Biomedical Research Centre; and Endorsed by the Irish Critical Care - Clinical Trials Group, co-ordinated in Ireland by the Irish Critical Care - Clinical Trials Network at University College Dublin and funded by the Health Research Board of Ireland [CTN-2014-12]. This work uses Data / Material provided by patients and collected by the NHS as part of their care and support #DataSavesLives. The Data / Material used for this research were obtained from ISARIC4C. The COVID-19 Clinical Information Network (CO-CIN) data was collated by ISARIC4C Investigators. Data and Material provision was supported by grants from: the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), (award 200907), Wellcome Trust [Turtle, Lance-fellowship 205228/Z/16/Z], NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927), Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (award IS-BRC-1215-20013), and NIHR Clinical Research Network providing infrastructure support.
This work was possible due to the dedication and hard work of the Norwegian SARS-CoV-2 study team, and supported by grants from Research Council of Norway grant no 312780, and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner; The dedication and hard work of the Groote Schuur Hospital Covid ICU Team, and supported by the Groote Schuur nursing and University of Cape Town registrar bodies coordinated by the Division of Critical Care at the University of Cape Town; and supported by the COVID clinical management team, AIIMS, Rishikesh, India.
Matthew Hall and Christophe Fraser were supported by a Li Ka Shing Foundation award to Christophe Fraser.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the World Health Organization Ethics Review Committee (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site according to local requirements. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data from institutions who have agreed to third party sharing are available to researchers approved by the COIVD-19 Data Platform Data Access Committee. See https://www.iddo.org/covid19/data-sharing/accessing-data for details and the application form.
